Aclaris Therapeutics, Inc. (ACRS) Total liabilities 2017–2025
Aclaris Therapeutics, Inc. (ACRS) total liabilities at each fiscal year-end, per SEC filings.
$57.4MFY2025 · since FY2017: $18.2M → $57.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $57.4M | -11.4% |
| FY2024 | $64.8M | +61.0% |
| FY2023 | $40.2M | -29.4% |
| FY2022 | $57.0M | +5.8% |
| FY2021 | $53.9M | +62.6% |
| FY2020 | $33.1M | +16.7% |
| FY2019 | $28.4M | -53.0% |
| FY2018 | $60.4M | +231.2% |
| FY2017 | $18.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ACRS financial trends
ACRS RevenueACRS Net incomeACRS Net marginACRS Gross profitACRS Gross marginACRS Operating incomeACRS Operating marginACRS Operating cash flowACRS Free cash flowACRS Capital expendituresACRS Return on equityACRS Stock buybacksACRS Dividends paidACRS Total assetsACRS Shareholders’ equityACRS overview →